SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

IM-3050

IMNM·Immunome Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
At least 5-7 years, assuming successful Phase 1, Phase 2, and Phase 3 trials. The drug is currently in Phase 1 dose-escalation with no efficacy data yet.
Why 2/10
No hard, dated binary catalyst is scheduled for IM-3050 in the next ~12 months. The drug is in Phase 1 dose-escalation (first patient dosed July 2026) with no announced timeline for data readout. Immunome's primary near-term catalyst is varegacestat's PDUFA date of April 28, 2027. IM-3050 is an early-stage pipeline asset that represents a small portion of the company's overall value.
Actionable Insight NEUTRAL

IM-3050 is an early Phase 1 program with no near-term binary catalyst. The next meaningful update would likely be initial safety/dosing data from the ongoing Phase 1 trial, but no timeline for that readout has been announced. Immunome's stock is primarily driven by varegacestat (PDUFA April 28, 2027) and IM-1021 (ASH 2026 data), not IM-3050.

Price Chart

Loading chart...

Executive Summary

IM-3050 is Immunome Inc.'s (Nasdaq: IMNM) lead radioligand therapy candidate, a fibroblast activation protein (FAP)-targeted treatment that delivers radioactive lutetium-177 to FAP-expressing advanced solid tumors. The drug entered Phase 1 clinical development in July 2026 with the first patient dosed in an open-label, multicenter dose-escalation and expansion study. Preclinical data were presented at AACR 2024. IM-3050 is an early-stage asset within Immunome's broader pipeline, which is currently dominated by varegacestat (PDUFA April 28, 2027 for desmoid tumors) and the IM-1021 ADC program. No near-term binary catalyst is scheduled for IM-3050 specifically, making it a minor driver of the stock's valuation at this stage.

How It Works

IM-3050 is a radioligand therapy, a type of targeted radiation treatment. It works by attaching a radioactive isotope (lutetium-177) to a molecule that seeks out and binds to fibroblast activation protein (FAP), a protein found on the surface of cells in many types of solid tumors. Once bound, the radiation delivers a localized dose to kill tumor cells while largely sparing healthy tissue. Think of it as a smart bomb that delivers radiation directly to cancer cells.

Trial Status

IM-3050 is in an open-label, multicenter Phase 1 dose-escalation and expansion trial for patients with FAP-expressing advanced solid tumors. The first patient was dosed on July 20, 2026. The trial is evaluating safety, tolerability, dosimetry, pharmacokinetics, and preliminary antitumor activity. No interim data have been reported as of November 2026.

The Two-Sided Case

▲ Bull Case4
IM-3050 targets fibroblast activation protein (FAP), which is broadly expressed across many solid tumor types, giving it a potentially large addressable patient population if successfully developed.
As a radioligand therapy delivering lutetium-177 directly to FAP-expressing cells, IM-3050 leverages a validated modality (radioligand therapy) that has produced approved drugs like Lutathera.
Immunome has a strong institutional holder base (FMR LLC, BlackRock, State Street) and analyst consensus is strongly bullish (21 Buy/Strong Buy vs 2 Hold, mean price target $35.20 implying ~85% upside).
The company has a cash runway supported by $582.7 million as of mid-2026, providing resources to advance IM-3050 through early clinical development.
▼ Bear Case4
IM-3050 is in very early clinical development (Phase 1 dose-escalation), with no efficacy data yet and a high probability of failure typical of Phase 1 oncology assets.
The FAP-targeted radioligand therapy space is competitive, with multiple companies developing similar lutetium-177 FAP inhibitors, increasing the risk that IM-3050 may not achieve a differentiated profile.
Immunome reported a Q3 2026 net loss of $85.78 million and has been burning cash, with the company filing an S-3ASR shelf registration in November 2026, signaling potential future dilution.
Insider selling has been notable, with executives selling over $2.9 million in shares since August 2026, per SEC Form 4 filings.

Upcoming Catalysts

  • Initial safety and dosing data from the Phase 1 trial (no date announced)
  • Potential future expansion cohort data (no date announced)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Immunome Inc. 8-K IMNM ·Originating report

Sources · 6

Hover a chip for the title
1 morningstar.com2 markets.financialcontent.com3 biospace.com4 businesswire.com5 investing.com6 msn.com